<DOC>
	<DOCNO>NCT02157987</DOCNO>
	<brief_summary>Epistaxis present 90 % patient Rendu - Osler . They involve significant difference 2 sex . They often appear childhood adolescence present three-quarters patient age 20 year . These epistaxis increase frequency volume age 60 2/3 patient . Epistaxis spontaneous , repetitive recur . They highly variable duration , intensity frequency occurrence . Some patient may 40 monthly episode mean duration 5 minute bleed chronic anemia sometimes acute anemia transfusion need source . These epistaxis stigmatize patient inevitably affect quality life social skill . The various propose ( cauterization , intra- mucosal injection , laser selective h√©mostatses , embolization surgical dermoplasties ) allow short-term remission . Bevacizumab antiangiogenic use treatment colorectal cancer . It also use ophthalmology intravitreal reduce vascular proliferation glaucoma retinopathy certain corneal neovascularization . In 2009 , Prithviraj report use bevacizumab injection treat pulmonary arteriovenous malformation patient Rendu - Osler . The result doubly interest include save action epistaxis decrease frequency duration . This communication prompt author focus medication . The product use local submucosal injection intranasal laser couple satisfactory result objectify decrease number epistaxis , reduce blood transfusion improve social life . The use local instillation bevacuzimab represent way forward treatment epistaxis .</brief_summary>
	<brief_title>Treatment Hereditary Hemorrhagic Telangiectasia Nasal Mucosa Intranasal Bevacizumab : Search Effective Dose</brief_title>
	<detailed_description />
	<mesh_term>Telangiectasis</mesh_term>
	<mesh_term>Telangiectasia , Hereditary Hemorrhagic</mesh_term>
	<mesh_term>Bevacizumab</mesh_term>
	<criteria>patient RenduOslerWeber disease patient iterative epistaxis ( least 10 per month ) patient without treatment 3 month usual technique ( epistaxis ) patient speak french fluently patient write consent affiliation social security woman effective contraception treatment 6 month stop General criterion : Pregnant woman , breastfeed Hypersensitivity active substance excipients Hypersensitivity product Chinese hamster ovary cell human humanize recombinant antibody Inability undergo medical monitoring due reason geographical , social psychological Patient guardianship Patient include another biomedical research protocol Related medical history criterion : Uncontrolled hypertension ( systolic BP &gt; = 150 mmHg / Diastolic BP &gt; = 100 mmHg ) Thrombocytopenia &lt; 100 G / L Taking NSAIDs within ten day prior inclusion Anticoagulant therapy thrombolytic within 28 day inclusion Tumor , genetic predisposition bleeding , coagulopathy , patient receive treatment full anticoagulant dose event thromboembolism prior inclusion Major surgery within 28 day prior inclusion History thromboembolic disease within 6 month prior enrollment Arteriovenous malformation localize brain , liver lung scanner old 5 year History heart failure Patients proteinuria / creatinine great 2g / g</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>January 2015</verification_date>
	<keyword>telangietasia hereditary hemorragic</keyword>
	<keyword>epistaxis</keyword>
	<keyword>safety</keyword>
	<keyword>quality life</keyword>
	<keyword>bevacizumab</keyword>
	<keyword>spray</keyword>
</DOC>